3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Cyst
2
Neoplasms
2
Melanoma
2
Stomach Neoplasms
1
Stage IB Cervical Cancer FIGO 2018
1
Spondylitis, Ankylosing
1
Psoriasis
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lupus Erythematosus, Systemic
1
Kidney Neoplasms
1
Inflammatory Bowel Diseases
1
Hepatitis B, Chronic
1
Giant Cell Tumor of Bone
1
Crohn Disease
1
Colitis, Ulcerative
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Bone Neoplasms
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Arthritis, Reactive
1
Interventions
Sunitinib
17
Sorafenib
16
pazopanib
7
cabozantinib
7
Axitinib
7
Blood Specimen Collection
6
Bevacizumab
6
avelumab
5
Immunohistochemistry
5
temsirolimus
4
pembrolizumab
3
Watchful Waiting
3
Specimen Handling
3
Immunotherapy
3
Gene Expression Profiling
3
Everolimus
3
Urine Specimen Collection
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Flow Cytometry
2
Data Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
lenvatinib
1
fluoroazomycin arabinoside
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Renal Cell
×
Methods
×
Clear all
NCT04222374
2020-07-13
Uro-DNA - GWAS
University Hospital, Bordeaux
Completed
200 enrolled